×
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
S&P 500   3,818.83 (-0.07%)
DOW   31,029.31 (+0.27%)
QQQ   283.86 (+0.11%)
AAPL   139.10 (+1.21%)
MSFT   260.00 (+1.37%)
META   163.83 (+1.96%)
GOOGL   2,233.00 (-0.32%)
AMZN   108.82 (+1.32%)
TSLA   685.35 (-1.81%)
NVDA   155.40 (-2.77%)
NIO   21.87 (-2.19%)
BABA   116.16 (-0.51%)
AMD   77.99 (-3.45%)
MU   56.05 (-3.13%)
CGC   3.50 (-3.05%)
T   20.95 (+1.65%)
GE   63.69 (-3.32%)
F   11.52 (-2.46%)
DIS   95.74 (-0.19%)
AMC   13.63 (+1.87%)
PFE   50.94 (+0.55%)
PYPL   71.54 (-0.39%)
NFLX   178.50 (-0.61%)
NASDAQ:CNAT

Conatus Pharmaceuticals Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$2.20
$2.30
50-Day Range
$0.56
$1.34
52-Week Range
$0.23
$1.07
Volume
58,264 shs
Average Volume
1.28 million shs
Market Capitalization
$74.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Receive CNAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Conatus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNAT Stock Forecast (MarketRank)

Overall MarketRank

1.17 out of 5 stars

Medical Sector

1207th out of 1,432 stocks

Pharmaceutical Preparations Industry

594th out of 685 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
Conatus Pharmaceuticals logo

About Conatus Pharmaceuticals (NASDAQ:CNAT)

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidate includes Emricasan, an orally active caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for portal hypertension; for liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function. The company is also developing CTS-2090, an orally active inhibitor of caspase 1, which is in preclinical development stage for treating chronic diseases involving inflammasome pathways. The company has a collaboration agreement with Novartis to conduct three Phase IIb clinical trials. Conatus Pharmaceuticals Inc. was founded in 2005 and is headquartered in San Diego, California.

CNAT Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNAT
Fax
N/A
Employees
30
Year Founded
N/A

Company Calendar

Last Earnings
5/01/2020
Today
6/29/2022

Profitability

Net Income
$-11.39 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$21.72 million
Book Value
$0.53 per share

Miscellaneous

Free Float
N/A
Market Cap
$74.96 million
Optionable
Optionable
Beta
1.84














Conatus Pharmaceuticals Frequently Asked Questions

How were Conatus Pharmaceuticals' earnings last quarter?

Conatus Pharmaceuticals Inc (NASDAQ:CNAT) issued its quarterly earnings results on Friday, May, 1st. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.10). Conatus Pharmaceuticals had a negative trailing twelve-month return on equity of 48.22% and a negative net margin of 52.42%.
View Conatus Pharmaceuticals' earnings history
.

Who are Conatus Pharmaceuticals' key executives?

Conatus Pharmaceuticals' management team includes the following people:
  • Dr. Steven J. Mento, Co-Founder, Pres, CEO & Director (Age 67)
  • Dr. Keith W. Marshall MBA, Ph.D., Exec. VP, COO & CFO (Age 51)
  • Dr. David T. Hagerty, Exec. VP of Clinical Devel. (Age 64)
  • Dr. Alfred P. Spada, Co-Founder, Exec. VP of R&D and Chief Scientific Officer (Age 61)
  • Mr. Alan R. Engbring, Exec. Director of Investor Relations & Corp. Communications

What other stocks do shareholders of Conatus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conatus Pharmaceuticals investors own include KNOT Offshore Partners (KNOP), Trevena (TRVN), PPL (PPL), (CASC) (CASC), Vaxart (VXRT), Antares Pharma (ATRS), Dextera Surgical (DXTR), Novavax (NVAX), Exelixis (EXEL) and Geron (GERN).

What is Conatus Pharmaceuticals' stock symbol?

Conatus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNAT."

What is Conatus Pharmaceuticals' stock price today?

One share of CNAT stock can currently be purchased for approximately $2.26.

How much money does Conatus Pharmaceuticals make?

Conatus Pharmaceuticals (NASDAQ:CNAT) has a market capitalization of $74.96 million and generates $21.72 million in revenue each year.

How many employees does Conatus Pharmaceuticals have?

Conatus Pharmaceuticals employs 30 workers across the globe.

How can I contact Conatus Pharmaceuticals?

Conatus Pharmaceuticals' mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The official website for Conatus Pharmaceuticals is www.conatuspharma.com. The biotechnology company can be reached via phone at 858-376-2600 or via email at [email protected].

This page (NASDAQ:CNAT) was last updated on 6/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.